Aminoindanes, piperazines, and pipradrol derivatives are novel psychoactive substances found in "Ecstasy" tablets as replacements for 3,4-methylenedioxymethamphetamine (MDMA) or substances sold as "ivory wave." The pharmacology of these MDMA-and methylphenidate-like substances is poorly known. We characterized the pharmacology of the aminoindanes 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodoaminoindane (5-IAI), and 2-aminoindane (2-AI), the piperazines meta-chlorophenylpiperazine (m-CPP), trifluoromethylphenylpiperazine (TFMPP), and 1-benzylpiperazine (BZP), and the BZP, D2PM, and 2-DPMP lacked serotonergic activity and TAAR 1 binding, in contrast to the aminoindanes and phenylpiperazines. In summary, all of the substances were monoamine transporter inhibitors, but marked differences were found in their 3 DAT vs. SERT inhibition profiles, release properties, and receptor interactions. The pharmacological profiles of D2PM and 2-DPMP likely predict a high abuse liability.
Introduction
New psychoactive substances [1] are constantly emerging on the illicit drug market. Many of these novel designer substances are amphetamine derivatives and typically marketed as "bath salts", "research chemicals" or "legal highs" via the Internet [2] . Pharmacological information is typically not available for these newly emerging designer substances. Interactions with the norepinephrine (NE), dopamine (DA), and serotonin (5-hydroxytryptamine ) transporters (NET, DAT, and SERT, respectively) to block or release monoamines can be expected based on the amphetamine-like core structure of many of these substances. In addition, chemical modifications typically alter absolute or relative potencies at the NET and DAT relative to the SERT or substrate release properties, thereby affecting stimulant-like and reinforcing properties [3, 4] . Additional interactions with the 5-HT 2A receptor may result in hallucinogenic-like actions. Substances that predominantly act on the NET and DAT have stimulant-like properties similar to amphetamine, whereas substances that mostly act on the SERT may have more "empathogenic" properties similar to 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) [4, 5] . Assessing the in vitro pharmacological profiles of novel substances is a relatively rapid approach for gaining a first impression of their potential clinical effects and toxicology, in addition to user reports. Accordingly, the pharmacology of many novel designer cathinones ("bath salts" and "research chemicals") has recently been characterized in vitro [4, [6] [7] [8] [9] [10] . The aim of the present study was to describe the effects on monoamine uptake and release of novel psychoactive substances that are not cathinones, but have been introduced into the illicit drug market as "legal highs" to typically mimic the subjective effects of MDMA or amphetamine-type stimulants. Aminoindanes, such as 5,6-methylenedioxy-2-aminoindane (MDAI) and 5-iodoaminoindane (5-IAI), became increasingly available over the Internet starting in 2010 as legal and, in the case of MDAI, allegedly less-neurotoxic alternatives to MDMA [11] [12] [13] . Piperazines have been used for more than a decade [14] and are commonly found in Ecstasy pills as substitutes for MDMA [15, 16] . Toxicity associated with the use of "ivory wave," which contains the pipradrol derivative desoxypipradrol (2-diphenylmethylpiperidine Similar data on MDMA and other novel psychoactive substances have previously been published [4, 6] . We determined the potencies of the compounds to inhibit the human NET, DAT, and SERT. We tested whether the compounds induce the transporter-mediated release of NE, DA, and 5-HT and characterized the binding affinities of the compounds for monoamine transporters,  1 and  2 adrenergic receptors, dopamine D 1 -D 3 receptors, 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors, the histamine H 1 receptor, and trace amine-associated receptor 1 (TAAR 1 ). Most of the substances examined herein were previously studied using rodent transporters, but only a few were also studied using human transporters and receptors [7] . However, more comprehensive analyses are needed at both human transporters and receptors Similar data on novel designer cathinones and classic stimulants, including amphetamine, methamphetamine, MDMA, and cocaine have previously been obtained using identical methods [4, 6] .
Methods

6
Chemicals
MDMA, methylphenidate, m-CPP, TFMPP, and BZP were supplied by Lipomed (Arlesheim, Switzerland), and 5-IAI, 2-AI, 2-DPMP, and D2PM were supplied by Cayman Chemicals (Ann Arbor, MI, USA) as racemic hydrochloride salts (purity > 98.5%). MDAI was synthesized as a racemic hydrochloride salt in our laboratory according to Nichols et al. [20] 
Monoamine uptake transport inhibition
The inhibition of the NET, SERT, and DAT was assessed in human embryonic kidney 293 (HEK 293) cells that stably expressed the human NET, SERT, and DAT [21] as previously described in detail [22] . the labeled monoamines at room temperature. Uptake was stopped after 10 min by separation of the cells from the buffer by rapid centrifugation at high speed through silicone oil [22] . The uptake times were based on kinetic evaluations showing that uptake is complete after 5 min [22] . The centrifugation tubes were frozen in liquid nitrogen and cut to separate the cell pellet from the silicone oil and assay buffer layers. The cell pellet was lysed. Scintillation fluid was added, and radioactivity was counted on a beta-counter. Nonspecific uptake was determined for each experiment in the presence of 10 M fluoxetine for SERT cells, 10 M nisoxetine for NET cells, 7 and 10 M mazindol for DAT cells and subtracted from the total counts to yield specific uptake (100%). Nonspecific uptake was < 15% of total uptake. The data were fit by non-linear regression to variable-slope sigmoidal dose-response curves, and IC 50 values were calculated using Prism (GraphPad, San Diego, CA, USA).
DAT/SERT ratios were calculated as 1/DAT IC 50 :1/SERT IC 50 . The DAT/SERT ratio is considered useful to predict the characteristics of the psychoactive effects of novel psychoactive substances [4, [23] [24] [25] . Higher relative potency at the DAT may indicate a higher abuse potential while relatively increased activity on the 5-HT system is linked to reduced abuse potential and more MDMA-like psychotropic effects [25] .
Stimulant amphetamines such as methamphetamine exhibit a DAT/SERT ratio >10, while MDMA and other substances with MDMA-like psychotropic effects exhibit a DAT/SERT ratio close to 0.1 [4, 26] .
Transporter-mediated monoamine release
We studied the effects of 100 µM of the test compounds on transportermediated NE, 5-HT, and DA efflux in HEK 293 cells that overexpressed the respective human monoamine transporter as previously reported in detail [4] . washing the cells twice with cold buffer. We quantified the radioactivity that remained in the cells. Nonspecific "pseudo-efflux," which arises from substrate that diffuses out of the cells and reuptake inhibition [27, 28] , was assessed for each experiment using the transporter inhibitors nisoxetine (NET cells), citalopram (SERT cells), and mazindol (DAT cells) at 10 µM as negative control conditions. We then used analysis of variance followed by Dunnett's test to compare test drug-induced monoamine release with nisoxetine, citalopram, and mazindol (negative controls).
Compounds that induced significantly higher maximal monoamine efflux compared with the respective transporter inhibitors, which induced slight nonspecific release, were considered monoamine releasers. MDMA was used as a positive control condition in each experiment. Previously published data on cathinones [6] were obtained from the same experiments and tested along-side with the drugs described here. Therefore the data on MDMA are the same as previously published [6] and data on cathinones [6] can be compared with those obtained with the data shown here. All of the conditions were normalized to radioactive counts of the assay buffer control condition. The assays allowed qualitative classification of a drug as a releaser or nonreleaser at 100 µM, but not quantitative comparisons between transporters.
Radioligand binding assays
The radioligand binding assays were performed as described previously [4, 22, 29] . Briefly, membrane preparations of HEK 293 cells (Invitrogen, Zug, Switzerland)
that overexpress the respective transporters [21] or receptors (human genes, with the exception of TAAR 1 receptors that were rat/mouse; [29] regression curves for a one-site model using three to five independent 10-point concentration-response curves for each compound. K i (affinity) values, which correspond to the dissociation constants, were determined using the Cheng-Prusoff equation. Similarly obtained data on MDMA has previously been published [4, 6] .
Results
Monoamine uptake transporter inhibition
The effects of the test compounds on monoamine transporter function are presented in Fig. 2 
Transporter-mediated monoamine release
The effects of the test compounds on the transporter-mediated release of NE, DA, and 5-HT from transmitter-preloaded cells are depicted in [4, 6] . Binding potencies at the monoamine transporters were typically weak, except for the high-affinity (< 100 nM) binding of the pipradrol derivatives at the DAT.
Binding affinities
Discussion
All of the novel substances characterized in the present study interacted with the monoamine transporters. High potency of a compound to inhibit the catecholamine transporter NET and DAT in vitro is associated with greater psychostimulant potency in humans [4] . These compounds typically exhibit a DAT/SERT ratio > 1 and a high abuse potential [4] . Predominant drug activity at the SERT [22] and a DAT/SERT inhibition ratio of typically 0.01 -0.1 are expected to result in subjective drug effects similar to those of MDMA or other empathogens [4, 6] . These serotonergic compounds produce subjective well-being and enhanced empathy and sociability in humans without marked psychostimulation [5, 30] .
Additionally, compounds which predominantly act on SERT and NET [6] have been associated with 5-HT syndrome, hyperthermia and resulting organ failure.
Furthermore, compounds which act as monoamine releasers (i.e., MDMA or methamphetamine [4, 6] ) enter the intracellular space via the transporter. In contrast to pure transporter blockers (i.e., cocaine), monoamine releasers are expected to have more subsequent intracellular pharmacological and neurotoxic consequences [31, 32] .
The in vitro pharmacological profiles of the compounds studied herein may be useful to predict the clinical effects according to the associations noted above. The profiles can also be compared with those of cocaine and a series of recreationally used amphetamine and cathinone derivatives previously characterized using the same in vitro assays [4, 6] .
Aminoindanes
The aminoindanes 5-IAI and MDAI preferentially inhibited the NET and SERT and less potently inhibited the DAT, similar to MDMA [4, 6] , but with approximately two-fold lower potency. 5-IAI and MDAI released 5-HT through the SERT, similar to MDMA. MDAI also shared the NE-releasing property and receptor binding profile of MDMA [4, 6] . Similar inhibitory effects of 5-IAI and MDAI on human monoamine transporters have recently been shown [7] , but no comparable data on monoamine release are available. In contrast to the human transporter studies, both MDAI and 5-IAI were relatively more potent SERT and DAT vs. NET inhibitors in rat brain synaptosomes [33] . Similar to our data, MDAI released 5-HT, but not DA, and 5-IAI released both 5-HT and DA from rat brain synaptosomes [33] . 5-IAI and MDAI substituted for MDMA in drug discrimination studies [20, 34] , but were considered less neurotoxic than MDMA [20, 34, 35] . This profile may increase the popularity of these aminoindanes [13] . The comparable monoamine transporter inhibition and release profile to MDMA [4, 6] would predict that MDAI has very similar subjective effects to MDMA, and this is supported by user reports [12, 36] .
Rare severe complications include serotonin syndrome and hyperthermia [36] , also 13 similar to MDMA. In contrast to MDAI and MDMA [4, 6] , 5-IAI exhibited relevant binding to 5-HT receptors, including the 5-HT 2A receptor that is implicated in the action of hallucinogens [37] . 5-IAI is also considered a less potent MDMA substitute, but dysphoria, anxiety, and hallucinations have also been reported [13] . In contrast to the substituted aminoindanes, 2-AI selectively inhibited the NET, but not the DAT or SERT. This profile is relatively similar to BZP in the present study, but most other amphetamines also typically more potently inhibit the DAT [4, 6] . 2-AI also released NE and DA. No comparable data on the pharmacology of 2-AI have been reported.
Based on the profile in the present study, 2-AI likely has only mild psychostimulant effects in humans.
Piperazines
Although piperazines have been widely used since the 1990s, and their pharmacology and toxicology have been reviewed [14, [38] [39] [40] [41] , only few and conflicting original data are available on their pharmacological mechanism. In the present study, BZP inhibited the NET and released DA. Early studies in rats found that BZP inhibits the uptake of not only NE and DA, but also 5-HT [42] , which is very inconsistent with our data obtained with human transporters and recent rat studies [43] . Similar to the present study, BZP produced the transporter-mediated release of DA, but not 5-HT from rat synaptosomes in vitro [43] . BZP enhanced electrically induced NE release from rabbit arteries [44] , likely reflecting its NETinhibiting properties. BZP also induced a robust increase in extracellular DA in vivo, but only weakly increased 5-HT dialysate levels at higher doses [43] . Speculations that BZP may act as an α 2 -adrenergic antagonist [44] in humans seem unlikely, given the lack of binding to this and other monoamine receptors in the present study. We 14 also did not confirm the results of an early rat study that reported the 5-HT antagonistic properties of BZP [45] . Thus, our data indicate that BZP is an indirect DA and NE agonist without serotonergic properties. In animals, BZP induced place preference in rats [46] and was self-administered in monkeys, and it substituted for amphetamine in discrimination studies [47] . In humans, 100 mg BZP produced subjective and cardiostimulant effects similar to 7.5-10 mg amphetamine [48, 49] , consistent with the five-to 10-fold lower potency of BZP at the NET and DAT compared with amphetamine [4] . In healthy women, a dose of 200 mg BZP produced cardiostimulant and subjective effects that were considered similar to those generally seen with stimulants [50] , but a direct comparison with other compounds is lacking.
The clinical toxicity of BZP mainly includes hallucinations, agitation, seizures, and hyperthermia [40] . properties and does not maintain responding for amphetamine [47] . Additionally, TFMPP reduced the self-administration of BZP and responding for cocaine [47] .
Altogether, the preclinical data indicate that both m-CPP and TFMPP are both indirect and direct serotonergic agonists without relevant dopaminergic activity.
However, their precise interaction with the human SERT and the nature of their serotonergic action in vivo require further investigations. m-CPP is frequently found in Ecstasy pills as a replacement for MDMA [57, 58] . . In humans, the combination of BZP and TFMPP produced stimulation and "good" drug effects, but no euphoria [65] . The BZP-TFMPP combination was not well tolerated at higher doses and frequently produced agitation, anxiety, hallucinations, and vomiting [66] , whereas these adverse effects were infrequently observed after MDMA administration in a similar laboratory study [67] . As noted above, the BZP-TFMPP combination has reduced reinforcing properties compared with BZP alone [47] , consistent with the abuse-lowering effects of 5-HT.
Pipradrol derivatives
D2PM and 2-DPMP were selective catecholamine transporter inhibitors without transporter-mediated substrate-releasing properties, similar to methylphenidate. 2-DPMP was a DAT/NET inhibitor that was equally potent to methylphenidate, whereas D2PM was less potent. Consistent with our findings, 2-DPMP has been previously shown to inhibit the human NET and DAT, but not SERT [7] , and block the uptake of DA and NE into synaptic rat brain vesicles [68, 69] . 2-DPMP also blocked NE uptake into rabbit aortic strips, but did not induce NE release [70] , also consistent with our results. Compared with classic stimulants, 2-DPMP was a 10-fold more potent DAT blocker than cocaine [4] . Consistent with the greater DAT-inhibiting potency, 2-DPMP also more potently increased electrically evoked DA release in rat brain slices compared with cocaine [71] . We found no other data on the monoamine uptake and releasing properties of D2PM. The pharmacological profile of the pipradrol derivatives was very similar to the pyrovalerone cathinones MDPV and naphyrone that were characterized in the same assays [4] , although naphyrone also inhibits the SERT. MDPV and naphyrone rather than 2-DPMP have been found in some samples of "ivory wave" [72] . Similar to MDPV [4] and naphyrone [73] , 2-DPMP and D2PM are highly lipophilic. Compared with methylphenidate, 2-DPMP lacks polar groups that are typically targeted by metabolic enzymes, resulting in a longer half-life [74, 75] . The clinical toxicity of 2-DPMP and D2PM is long-lasting (24-72 h) and involves sympathomimetic stimulation and predominantly psychiatric symptoms, including agitation, hallucinations, and insomnia [17, 18] . Altogether, the pipradrol derivatives are potent and selective catecholamine uptake inhibitors, consistent with their potent and prolonged psychostimulant actions. The pharmacological profile is also likely associated with high abuse liability and an increased risk of psychiatric complications.
TAAR 1 binding
The aminoindanes and phenylpiperazines, but not BZP or pipradrol derivatives, exhibited potent TAAR 1 binding affinity comparable to MDMA [4, 6] . In the present series, all of the serotonergic compounds also bound TAAR 1 , whereas the affinity for TAAR 1 has previously been documented for amphetamine and methamphetamine [4] , which only weakly interact with the SERT. Drug activity at the SERT and TAAR 1 are both considered to counteract the abuse liability associated with dopaminergic drug properties. Higher serotonergic vs. dopaminergic activity has been associated with a lower abuse potential of a drug [4, [23] [24] [25] . Amphetamines such as MDMA and methamphetamine have been shown to inhibit their own neurochemical and locomotor stimulant effects via TAAR 1 activation [76] . The lack of serotonergic activity and lack of TAAR 1 -mediated "auto-inhibition" in particular with the pipradrol derivatives may contribute to the more stimulant-like and addictive properties of this class of designer compounds compared with classic amphetamines, including MDMA [4] .
Limitations
Knowing the mechanism of action of novel compounds in vitro helps to predict potential clinical effects and abuse potential. However, many additional factors also play a role such as brain tissue penetration and pharmacokinetics which need to be further assessed in vivo.
Conclusion
In summary, the aminoindanes, 5-IAI and MDAI inhibited the SERT and 
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